Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00699374 · ClinicalTrials.gov registry record · Phase 3
Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,075
- Enrollment target
NCT00699374: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00699374 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 1,075 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00699374, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,075 participants
- Enrollment target
Study Summary
The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Study treatment may be adjusted based on patient tolerance. and will be given until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. After discontinuation of study treatment, patients will be followed up in order to collect information on further antineoplastic therapy and survival.
Primary Outcome
Overall survival is the duration from randomization to death. For participants who are alive, overall survival was censored at the last contact.
Interventions
- DRUG sorafenib
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,075 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
Why NCT00699374 stopped before completion
NCT00699374 is an interventional study that assigns participants to a tested intervention. Its 1,075 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (39% higher).
The record links to 0 conditions, and to 2 interventions - of which sorafenib is the first listed.
NCT00699374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00699374 about?
NCT00699374 is a clinical study titled "Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer". The study will evaluate the efficacy and safety of sunitinib (Arm A), given at 37.5 mg orally once daily, compared to sorafenib (Arm B), given orally at 400 mg twice daily, in patients with inoperable liver cancer. A total number of 1200 patients will be enrolled, 600 on Arm A and 600 on Arm B. Stud...
What is the current status of trial NCT00699374?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,075 participants. The study started on 2008-07. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00699374?
The interventions under investigation include: sorafenib (DRUG), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT00699374?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00699374's enrollment target sits among peer trials
1,075 271st of 2000 higher than 1,730 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06159673 · 1,074 participants · Phase 2
ACP-204 in Adults With Alzheimer's Disease Psychosis
- NCT06751043 · 1,072 participants · NA
Preoperative Fasting vs. Not Fasting in Critically Ill Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia